Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Merck & Co., Inc./ 10-Q

Quarterly Report · 10-Q

Merck & Co., Inc.

MRKNYSEEQUITYCurrent

Quarterly Report

Filed Aug 7, 2026Accepted Aug 7, 2026, 4:11 PM EDTCIK 310158Accession 0000310158-26-000212
View company →Permanent SEC source ↗
Share

Company context

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Current securities

MRKNYSE · EQUITY · Current

Recent company filings

  1. Results of Operations and Financial ConditionOct 29, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 13, 2026
  3. 4 filingAug 13, 2026
  4. 144 filingAug 13, 2026
  5. 4 filingAug 13, 2026

Registered securities in this filing

Merck & Co., Inc. · 10-Q · Filed 2026-08-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock ($0.50 par value)

Symbol
MRK
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

1.875% Notes due 2026

Symbol
MRK/26
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

3.250% Notes due 2032

Symbol
MRK/32
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-4

Dimensions: us-gaap:StatementClassOfStockAxis

2.500% Notes due 2034

Symbol
MRK/34
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-5

Dimensions: us-gaap:StatementClassOfStockAxis

1.375% Notes due 2036

Symbol
MRK 36A
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-6

Dimensions: us-gaap:StatementClassOfStockAxis

3.500% Notes due 2037

Symbol
MRK/37
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-7

Dimensions: us-gaap:StatementClassOfStockAxis

3.700% Notes due 2044

Symbol
MRK/44
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-8

Dimensions: us-gaap:StatementClassOfStockAxis

3.750% Notes due 2054

Symbol
MRK/54
Exchange
NYSE
Classification
DEBT
Filing context

Context: c-9

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000031015826000212 · 8 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.